Mavenir Introduces Mobile Business Fabric™ to Transform Business Communications for Deskless Mobile Workers
8.10.2019 15:00:00 EEST | Business Wire | Press release
Mavenir, the industry’s only end-to-end, cloud-native Network Software Provider, today announced its Mobile Business Fabric™, a dynamic and fluid business communications framework designed to meet the evolving digital needs of businesses as mobility becomes a primary driver and customers demand change.
Mavenir’s Mobile Business Fabric™ consists of a portfolio of integrated business solutions with a focus on enabling deskless, mobile workers for businesses of all sizes—from SMBs to large enterprises. This portfolio integrates mobile voice, mobile video, rich communication services (RCS) and SMS messaging, voicemail, interactive voice response (IVR), chatbots, SpamShield™ fraud management and monetization enablers into secure, carrier-grade cloud offerings.
These are combined with digital enablement capabilities for provisioning, onboarding, and invoicing businesses via an intuitive, omnichannel interface. This embedded functionality avoids long, complex and costly integrations with the existing legacy business support systems (BSS) of the service provider or channel partner, accelerating time-to-market and time-to-revenue.
Mavenir’s Mobile Business Fabric solutions are currently deployed and under deployment in several Tier 1 MNOs in the US, UK, Spain, Germany, India and Japan.
“Mavenir’s vision is to transform mobile network economics and accelerate the business transformation for mobile operators and channel partners,” said Guillaume Le Mener, SVP and GM, Mobile Enterprise Solutions, Mavenir. “Mobile Business Fabric is a cohesive portfolio that provides true mobile-native experiences and addresses the deskless mobile user base to generate additional revenue streams, protect their existing customer base and reduce customer churn.”
Supporting Information:
- Today, 80% of the global workforce are mobile “deskless” first line workers and the top 8 deskless industries—agriculture, education, healthcare, retail, hospitality, manufacturing, transportation and construction—employ 2.7 billion employeesi.
- Deskless mobile workers require simplified workflows leveraging their powerful mobile devices on the go.
- Today, the majority of solutions in the market have been designed for office workers and then adapted to include some limited mobility capabilities. This can lead to user frustration, particularly for emerging mobile small and medium businesses (SMBs), which have been underserved.
Mavenir’s Mobile Business Fabric flips the paradigm over with a mobile-native portfolio that doesn’t require IT administrators, hardware investments, or complex device management, while providing seamless onboarding to help accelerate time to revenue.
“As an innovative and agile Software as a Service (SaaS) solution, Mavenir’s Mobile Business Fabric portfolio enables our global partners to target the Enterprise market, as well as the underserved SMB segment,” said Marek Wasilewski, SVP, Global Enterprise Channel. “Our disruptive solutions designed for the deskless mobile workers—who typically have an I want to do it myself and I want it now mentality—simplify onboarding, remove management complexity, and, ultimately, are focused on adding positive business outcomes."
The Mobile Business Fabric portfolio comes to market with the following solutions:
- Mobile Business Messaging — RCS Business Messaging as a service that enables MNOs to address the brands’ need to communicate with customers on the mobile messaging channel—including marketing campaigns (A2P) and chatbots (P2A)—leveraging Mavenir’s RBM Partner Ecosystem to accelerate time-to-revenue.
- Mobile Business Contact — Helping businesses of all sizes to minimize the number of missed business opportunities with a white label omni-channel contact center as a service (CCaaS) designed for quick and easy access. It enables seamless omni-channel (phone, email, chat, text-message, social) interactions with customers; with fast deployment using pre-built templates and API integrations with popular tools and AI platforms.
- Mobile Business Communications and Collaboration — unified communications and collaboration as a service (UCaaS) built on mobile call control elements, that leverages mobile network quality of service (QoS) enforcement as well as RCS messaging to allow businesses to text with both internal and external users, breaking the traditional restrictions of proprietary instant messaging implementations.
The Mobile Business Fabric solutions announced are available today as a service hosted from the Mavenir cloud or deployed in the service provider’s network. Mavenir is already adapting more products and solutions into the Fabric, expected in early 2020.
To learn more, visit Mavenir's Mobile Business Fabric page.
NOTE: Mavenir will be showcasing Mobile Business Fabric with live demos at Mobile World Congress 2019 Los Angeles. To request a meeting, visit https://mavenir.com/buzz/events/mwc-la-2019
About Mavenir:
Mavenir is the industry's only end-to-end, cloud-native network software provider. Focused on accelerating software network transformation and redefining network economics for Communications Service Providers (CSPs) by offering a comprehensive end-to-end product portfolio across every layer of the network infrastructure stack. From 5G application/service layers to packet core and RAN – Mavenir leads the way in evolved, cloud-native networking solutions enabling innovative and secure experiences for end users. Leveraging industry-leading firsts in VoLTE, VoWiFi, Advanced Messaging (RCS), Multi-ID, vEPC, and Virtualized RAN, Mavenir accelerates network transformation for more than 250+ CSP customers in over 130 countries, which serve over 50% of the world’s subscribers.
We embrace disruptive, innovative technology architectures and business models that drive service agility, flexibility, and velocity. With solutions that propel NFV evolution to achieve web-scale economics, Mavenir offers solutions to help CSPs with cost reduction, revenue generation, and revenue protection. Learn more at mavenir.com
Mavenir, the M logo, and CloudRange are trademarks owned by Mavenir Systems, Inc.
Copyright © 2019 Mavenir Systems, Inc. All Rights Reserved.
i Emergence: Rise of the Deskless Workforce, 2018
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191008005042/en/
Contact information
Maryvonne Tubb
Mavenir
PR@mavenir.com
Loren Guertin
MatterNow
mavenir@matternow.com
Kevin Taylor
GlobalResultsPR
mavenir@globalresultspr.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom